Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
1(10%)
Results Posted
88%(7 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
4
40%
Ph phase_1
2
20%
Ph not_applicable
1
10%
Ph phase_3
2
20%
Ph phase_4
1
10%

Phase Distribution

2

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(8)
Terminated(1)

Detailed Status

Completed8
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 24 (40.0%)
Phase 32 (20.0%)
Phase 41 (10.0%)
N/A1 (10.0%)

Trials by Status

completed880%
recruiting110%
terminated110%

Recent Activity

1 active trials
Showing 5 of 10
recruitingphase_2

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT07560150
completedphase_2

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT05539872
completedphase_3

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

NCT04460326
terminatedphase_2

Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

NCT03262116
completedphase_1

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

NCT05184868
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07560150Phase 2

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

Recruiting
NCT05539872Phase 2

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Completed
NCT04460326Phase 3

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

Completed
NCT03262116Phase 2

Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

Terminated
NCT05184868Phase 1

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

Completed
NCT03554486Phase 4

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

Completed
NCT03977727Phase 3

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

Completed
NCT02059174Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)

Completed
NCT01621776Not Applicable

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

Completed
NCT00624767Phase 2

A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10